JP4733980B2 - 感染症の予防および治療 - Google Patents
感染症の予防および治療 Download PDFInfo
- Publication number
- JP4733980B2 JP4733980B2 JP2004530234A JP2004530234A JP4733980B2 JP 4733980 B2 JP4733980 B2 JP 4733980B2 JP 2004530234 A JP2004530234 A JP 2004530234A JP 2004530234 A JP2004530234 A JP 2004530234A JP 4733980 B2 JP4733980 B2 JP 4733980B2
- Authority
- JP
- Japan
- Prior art keywords
- infection
- ceramide
- cells
- membrane
- acid sphingomyelinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
ライノウイルスでの実験結果から、種々のライノウイルス(HRV菌株14および16)によるヒト上皮細胞の感染によって、酸性スフィンゴミエリナーゼの活性化(図1)およびセラミドの遊離(図2)が起こることが示されている。
HIVは、本質的にウイルスのgp120分子がCD4受容体に結合することによってヒト細胞に感染する。gp120がCD4に結合しない場合には、HIVによる細胞の感染は単に無効となる。gp120分子はgp41分子と共に、gp120が三量体として存在する、オリゴマー複合体を形成する。Tリンパ球上でのCD4分子へのgp120の結合によって、gp120のコンフォメーションが変化する;特に、可変ループのコンフォメーションが変化し、そのため、いわゆる補助受容体結合部位が露出する。gp120は、この結合部位を介して補助受容体、通常サイトカイン受容体CCR5またはCXCR4に結合する。全体で、14を超える異なる補助受容体が同定されているが、CCR5またはCXCR4のみがin vivoで非常に重要であると思われる。細胞内へのウイルスの取り込みは、CD4へのHIVの結合および更なる補助受容体を介して開始される(クラパム(Clapham)P.R.,マックナイト(McKnight)A.(2001).HIV−1 receptors and cell tropism.British Medical Bulletin 58:43−59)。
病原性細菌およびウイルスによる感染に対するセラミド豊富な膜プラットフォームの重要性が、緑膿菌(Pseudomonas aeruginosa)による哺乳動物細胞の感染の例で示された。緑膿菌(P. aeruginosa)を感染させた後に、酸性スフィンゴミエリナーゼの活性化およびセラミドの遊離が、Chang上皮細胞、WI−38線維芽細胞、ex vivo肺線維芽細胞、ex vivo培養気管上皮細胞の感染後にin vitroと、気管上皮細胞においてin vivoの両方で認められた。感染後のセラミドの遊離はラフトで起こり、ラフトは遊離したセラミドによって、より大きな膜プラットフォームに再編成される。緑膿菌(P. aeruginosa)による感染後、遊離したセラミドおよび酸性スフィンゴミエリナーゼは、新たに形成された膜プラットフォームにおいて局在化する。
Claims (1)
- アミトリプチリン、イミプラミンまたはデシプラミンを活性成分として含む、嚢胞性線維症の予防および/または治療剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10239531.4 | 2002-08-23 | ||
DE10239531A DE10239531A1 (de) | 2002-08-23 | 2002-08-23 | Prophylaxe und Therapie von Infektionserkrankungen |
PCT/EP2003/009254 WO2004017949A2 (de) | 2002-08-23 | 2003-08-21 | Prophylaxe und therapie von infektionserkrankungen mit amitryptilin oder imipramin oder desipramin oder fgf oder einem anticeramid antikörper oder cyclodextrin oder nystatin oder filipin |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006505527A JP2006505527A (ja) | 2006-02-16 |
JP2006505527A5 JP2006505527A5 (ja) | 2007-05-31 |
JP4733980B2 true JP4733980B2 (ja) | 2011-07-27 |
Family
ID=31197464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004530234A Expired - Fee Related JP4733980B2 (ja) | 2002-08-23 | 2003-08-21 | 感染症の予防および治療 |
Country Status (10)
Country | Link |
---|---|
US (2) | US7812015B2 (ja) |
EP (1) | EP1531826B1 (ja) |
JP (1) | JP4733980B2 (ja) |
CN (1) | CN100502875C (ja) |
AT (1) | ATE508749T1 (ja) |
AU (1) | AU2003255468B2 (ja) |
CA (1) | CA2497582C (ja) |
DE (1) | DE10239531A1 (ja) |
ES (1) | ES2366895T3 (ja) |
WO (1) | WO2004017949A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1913955A1 (en) | 2006-10-19 | 2008-04-23 | Gerhard, Markus | Novel method for treating H.pylori infections |
WO2008112297A2 (en) * | 2007-03-13 | 2008-09-18 | Yale University | Methods of treating cancer by interfering with igf-i receptor signaling |
AU2008247368B2 (en) * | 2007-05-06 | 2013-10-10 | Sloan Kettering Institute For Cancer Research | Methods for treating and preventing GI syndrome and Graft versus Host disease |
DE102007063535A1 (de) * | 2007-12-21 | 2009-06-25 | Cycnad Gmbh & Co. Kg | Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose |
US10350277B2 (en) | 2011-09-07 | 2019-07-16 | Icahn School Of Medicine At Mount Sinai | Ceramidase and cell differentiation |
EP3903820A1 (en) * | 2012-05-25 | 2021-11-03 | Sloan-Kettering Institute for Cancer Research | An anti-ceramide antibodies |
EP2854910B1 (en) | 2012-06-01 | 2020-04-15 | Icahn School of Medicine at Mount Sinai | Ceramide levels in the treatment and prevention of infections |
JP6832158B2 (ja) | 2013-03-14 | 2021-02-24 | アイカーン スクール オブ メディシン アット マウント サイナイ | 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法 |
IL260690A (en) | 2018-07-19 | 2018-12-31 | Yeda Res & Dev | Sphingosine derivatives and their use against pulmonary bacterial infections |
DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
KR102422449B1 (ko) * | 2019-10-18 | 2022-07-20 | 연세대학교 산학협력단 | 결핵 및 비결핵항산균 감염 질환의 예방, 개선 또는 치료용 조성물 |
EP4181906A1 (en) | 2020-07-16 | 2023-05-24 | Harbins Ruhr Bioscience, Inc. | Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection |
WO2024085170A1 (ja) * | 2022-10-18 | 2024-04-25 | 国立研究開発法人国立精神・神経医療研究センター | ウイルス感染後遺症抑制剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5373005A (en) * | 1988-04-20 | 1994-12-13 | Merrell Dow Pharmaceuticals Inc. | Despiramine in the treatment of drug-resistant malarial infections |
FR2647343B1 (fr) * | 1989-05-24 | 1994-05-06 | Rhone Poulenc Sante | Nouvelle forme pharmaceutique poreuse et sa preparation |
US5233024A (en) * | 1991-04-09 | 1993-08-03 | The Brigham & Women's Hospital | Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use |
US5569677A (en) * | 1995-06-05 | 1996-10-29 | Smithkline Beecham Corporation | Diphenyl-2-propenoates for treating diseases associated with leukotriene B4 |
US5885786A (en) * | 1996-04-19 | 1999-03-23 | John Wayne Cancer Institute | Methods for screening of substances for inhibition of multidrug resistance |
AU2587399A (en) | 1998-02-11 | 1999-08-30 | Incyte Pharmaceuticals, Inc. | Human transport-associated molecules |
US6248528B1 (en) * | 1998-04-06 | 2001-06-19 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
JP2002531530A (ja) | 1998-12-04 | 2002-09-24 | カリフォルニア インスティテュート オブ テクノロジー | 治療用薬剤を含む超分子錯体 |
WO2000056890A1 (en) | 1999-03-19 | 2000-09-28 | Chiron Corporation | Human fgf gene and gene expression products |
MXPA02012660A (es) * | 2000-06-20 | 2004-05-14 | Atherogenics Inc | 1,3-(fenilo-substituido-bis)-2-propen-1-onas y su uso para el tratamiento de padecimientos transmitidos por el vcam-1. |
US6818216B2 (en) * | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
AUPS017702A0 (en) * | 2002-01-25 | 2002-02-14 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
-
2002
- 2002-08-23 DE DE10239531A patent/DE10239531A1/de not_active Withdrawn
-
2003
- 2003-08-21 AU AU2003255468A patent/AU2003255468B2/en not_active Ceased
- 2003-08-21 AT AT03792402T patent/ATE508749T1/de active
- 2003-08-21 US US10/524,815 patent/US7812015B2/en not_active Expired - Fee Related
- 2003-08-21 EP EP03792402A patent/EP1531826B1/de not_active Expired - Lifetime
- 2003-08-21 CA CA2497582A patent/CA2497582C/en not_active Expired - Fee Related
- 2003-08-21 JP JP2004530234A patent/JP4733980B2/ja not_active Expired - Fee Related
- 2003-08-21 CN CNB038244055A patent/CN100502875C/zh not_active Expired - Fee Related
- 2003-08-21 WO PCT/EP2003/009254 patent/WO2004017949A2/de active Application Filing
- 2003-08-21 ES ES03792402T patent/ES2366895T3/es not_active Expired - Lifetime
-
2010
- 2010-09-15 US US12/882,912 patent/US20110059949A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN100502875C (zh) | 2009-06-24 |
US20050209219A1 (en) | 2005-09-22 |
JP2006505527A (ja) | 2006-02-16 |
US7812015B2 (en) | 2010-10-12 |
AU2003255468B2 (en) | 2010-04-29 |
EP1531826A2 (de) | 2005-05-25 |
AU2003255468A1 (en) | 2004-03-11 |
US20110059949A1 (en) | 2011-03-10 |
ATE508749T1 (de) | 2011-05-15 |
CA2497582C (en) | 2013-11-19 |
CN1688316A (zh) | 2005-10-26 |
WO2004017949A2 (de) | 2004-03-04 |
DE10239531A1 (de) | 2004-03-04 |
CA2497582A1 (en) | 2004-03-04 |
WO2004017949A3 (de) | 2004-04-29 |
ES2366895T3 (es) | 2011-10-26 |
EP1531826B1 (de) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110059949A1 (en) | Prophylaxis and treatment of infectious diseases | |
Abbott‐Banner et al. | Dual PDE 3/4 and PDE 4 inhibitors: novel treatments for COPD and other inflammatory airway diseases | |
Wijagkanalan et al. | Intratracheally instilled mannosylated cationic liposome/NFκB decoy complexes for effective prevention of LPS-induced lung inflammation | |
RU2524304C2 (ru) | Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций | |
US20190031730A1 (en) | Formulation of mk2 inhibitor peptides | |
KR20210053303A (ko) | 신경퇴행성 장애를 치료하기 위한 rip 키나제의 억제 | |
JP4290764B2 (ja) | ヒトおよび動物のボルナ病ウイルスへの感染防止、ならびに情動障害およびbdv感染に関連するその他の障害の予防および治療に対するアダマンタンアミンまたはその構造的類縁化合物の使用 | |
WO2016131100A1 (en) | Methods of treating infectious diseases | |
JP2024509938A (ja) | SARS-CoV-2予防用ワクチン組成物 | |
JP6055845B2 (ja) | ペプチドおよびその使用 | |
US20230149438A1 (en) | Compositions and methods for treating and preventing prekallikrein-associated conditions | |
EP4171746A1 (en) | Materials and methods for the prevention and treatment of viral respiratory diseases | |
Ye et al. | Modulation of alveolar macrophage and mitochondrial fitness by medicinal plant-derived nanovesicles to mitigate acute lung injury and viral pneumonia | |
US20180042904A1 (en) | Compositions and methods for treating copd and other inflammatory conditions | |
US20220257614A1 (en) | Use of 12-lipoxygenase inhibitors in the treatment of covid-19 | |
US20230233595A1 (en) | Use of stat4 inhibitors for prevention and treatment of alzheimer's disease | |
Rai et al. | Nanotechnology as a shield against Covid-19: Cur-rent advancement and limitations. Viruses 2021; 13: 1224 | |
US20220177559A1 (en) | Compositions and methods to treat viral infection and co-morbidities | |
EP3160485B1 (en) | Grb-ehitsn inhibitory peptides | |
Predescu et al. | GrB-EH ITSN inhibitory peptides | |
Zwygart et al. | Development of Broad-spectrum β-cyclodextrins-Based Nanomaterials Against Influenza Viruses | |
DE102020207105A1 (de) | Wirkstoff sowie pharmazeutische Zusammensetzung zur Anwendung bei der Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2, hervorgerufenen Infektion und/oder Infektionskrankheit und/oder einer Folgeerkrankung davon | |
Jangir et al. | MODERN THERAPEUTICS, VACCINES AND FUTURE CHALLENGES IN THE TREATMENT OF COVID-19 | |
Ugen et al. | Anti-HIV activity of the opioid antagonist naloxone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060301 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060811 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091020 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100113 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100319 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100601 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100827 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100903 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101027 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110318 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110329 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110425 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140428 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4733980 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |